All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2006-000378-61 | A MULTICENTER, PHASE III, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY REGIMENS IN SUBJECTS WITH PREVIOUSLY UNTREATED METASTA... | 2016-01-08 | due-trials |
| Reported results | 2006-005552-33 | A PHASE Ib/II, OPEN LABEL, MULTICENTER STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF Apo2L/TRAIL ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB TO SUBJECTS WITH FOLLICULAR AND OTHER... | 2010-05-31 | due-trials |
| Reported results | 2006-006507-36 | A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY REGIMENS IN SUBJECTS WITH PREVIOUSLY TREATED METASTATI... | 2012-03-19 | due-trials |
| Reported results | 2006-006624-19 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE IIIb TRIAL COMPARING BEVACIZUMAB THERAPY WITH OR WITHOUT ERLOTINIB AFTER COMPLETION OF CHEMOTHERAPY WITH BEVACIZUMAB FOR THE FIRST-LINE TREATMENT... | 2014-11-24 | due-trials |
| Reported results | 2006-006626-26 | A Phase III, Multicenter, Placbo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination with Tarceva (erlotinib) Compared With Tarceva Alone For Tre... | 2019-12-23 | due-trials |
| Reported results | 2007-001666-32 | A PHASE II, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY OF THE SAFETY,PHARMACOKINETICS, AND EFFICACY OF MULTIPLE DOSES OF APOMAB ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB IN PATIE... | 2009-12-31 | due-trials |
| Reported results | 2008-003789-24 | A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF GDC-0449 AS MAINTENANCE THERAPY IN PATIENTS WITH OVARIAN CANCER IN A SECOND OR THIRD C... | 2010-12-31 | due-trials |
| Reported results | 2008-004945-27 | A PIVOTAL PHASE II, MULTICENTER, SINGLE ARM, TWO-COHORT TRIAL EVALUATING THE EFFICACY AND SAFETY OF GDC-0449 IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA | 2014-04-09 | due-trials |
| Reported results | 2008-006939-13 | A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND ACTIVITY OF MetMAb, A MONOVALENT ANTAGONIST ANTIBODY TO THE RECEPTOR MET, ADMINISTERED TO PATIENTS... | 2012-01-23 | due-trials |
| Reported results | 2009-009498-87 | A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study Of Xolair (Omaluzimab) In Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Anithist... | 2010-01-07 | due-trials |
| Reported results | 2009-010359-28 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF LEBRIKIZUMAB (MILR1444A)IN ADULT PATIENTS WITH ASTHMA WHO ARE INADEQUATELY CONTROLLE... | 2010-09-10 | due-trials |
| Reported results | 2009-013267-19 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-RANGING STUDY TO EVALUATE LEBRIKIZUMAB (MILR1444A) IN ADULT PATIENTS WITH ASTHMA WHO ARE NOT TAKING INHALED CORTICOSTEROIDS (MOLLY) | 2011-02-21 | due-trials |
| Reported results | 2009-015504-25 | An Open Label, Multicenter, randomized, phase III study to investigate the efficacy and safety of Bendamustine compared with Bendamustine + RO5072759 (GA101) in patients with Rituximabrefractory, in... | 2018-11-30 | due-trials |
| Completed, but no date, and reported results | 2010-019183-36 | A PHASE Ib/II, MULTICENTER, RANDOMIZED, SINGLE-MASKED, SHAM INJECTION−CONTROLLED STUDY OF SAFETY, TOLERABILITY, AND EVIDENCE OF ACTIVITY OF FCFD4514S INTRAVITREAL INJECTIONS ADMINISTERED MONTHLY OR EV... | bad-data | |
| Reported results | 2010-020101-32 | A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF METMAB IN COMBINATION WITH PACLITAXEL AND BEVACIZUMAB IN PATIENTS WITH METASTATIC, TRI... | 2016-03-08 | due-trials |
| Reported results | 2010-021170-11 | A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF INTRAVENOUS MEMP1972A IN THE PREVENTION OF ALLERGEN-IN... | 2012-01-05 | due-trials |
| Reported results | 2010-021577-37 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MLTA3698A IN COMBINATION WITH A DISEASE-MODIFYING ANTI-RHEUMATIC DRUG (DMARD) COMPARED WITH ADALIMUMAB... | 2012-09-19 | due-trials |
| Reported results | 2010-021926-37 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MABT5102A IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE | 2014-02-18 | due-trials |
| Reported results | 2010-022598-32 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, PHASE II STUDY TO EVALUATE THE IMPACT OF MABT5102A ON BRAIN AMYLOID LOAD AND RELATED BIOMARKERS IN PATIENTS WITH MILD TO MO... | 2014-04-17 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2010-022782-99 | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF XOLAIR (OMALIZUMAB) IN PATIENTS WITH CHRONIC IDIOPATHIC URTICARIA (CIU... | 2012-10-17 | bad-data |
| Reported results | 2010-022784-35 | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY STUDY OF XOLAIR (OMALIZUMAB) IN PATIENTS WITH CHRONIC IDIOPATHIC URTICARIA (CIU) WHO REMAIN SYMPTOMATIC DESPITE TREATMENT ... | 2012-11-22 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2010-022785-27 | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOSE-RANGING, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, RESPONSE DURATION AND SAFETY OF XOLAIR (OMALIZUMAB) IN PATIENTS WITH CHRONIC... | 2012-06-27 | bad-data |
| Reported results | 2010-023763-17 | A phase II double-blind placebo-controlled randomized study of GDC- 0941 or GDC-0980 with Fulvestrant versus Fulvestrant in advanced or metastatic breast cancer in patients resistant to aromatase in... | 2016-04-07 | due-trials |
| Reported results | 2011-000493-56 | A PHASE II, OPEN-LABEL, RANDOMIZED STUDY OF GDC-0980 VERSUS EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO HAVE PROGRESSED ON OR FOLLOWING VEGF-TARGETED THERAPY | 2015-06-23 | due-trials |
| Reported results Terminated | 2011-000711-85 | A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF MEGF0444A IN COMBINATION WITH CARBOPLATIN, PACLITAXEL AND BEVACIZUMAB IN PATIENTS WITH... | 2013-06-07 | due-trials |
| Reported results | 2011-000897-80 | PHASE II RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF rhuMAb BETA7 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS | 2013-03-20 | due-trials |
| Exempt, with results | 2011-001422-23 | A PHASE I, OPEN LABEL, DOSE ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB (MPDL3280A) ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT TO PATIENTS WITH LOCALLY ADVANCED OR METASTATIC... | 2018-09-30 | not-yet-due |
| Reported results | 2011-001867-28 | A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF MEGF0444A DOSED TO PROGRESSION IN COMBINATION WITH BEVACIZUMAB AND FOLFOX IN PATIENTS ... | 2014-02-24 | due-trials |
| Reported results | 2011-002224-40 | A randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MetMAb in Combination with Tarceva(erlotinib) in Patients with Met Diagnostic-Posit... | 2016-01-28 | due-trials |
| Reported results | 2011-002893-21 | A PHASE II, DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY EVALUATING THE SAFETY AND EFFICACY OF CARBOPLATIN/PACLITAXEL AND CARBOPLATIN/PACLITAXEL/BEVACIZUMAB WITH AND WITHOUT GDC-0941 IN PATIENT... | 2016-03-30 | due-trials |
| Reported results | 2011-003409-36 | A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Etrolizumab in Patients with Moderate to Severe Ulcerative Colitis | 2016-08-09 | due-trials |
| Reported results | 2011-003719-42 | A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF MetMAb IN COMBINATION WITH EITHER BEVACIZUMAB + PLATINUM + PACLITAXEL OR PEMETREXED + ... | 2015-11-30 | due-trials |
| Reported results | 2011-003997-10 | A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND DOSING REGIMENS OF MEMP1972A IN ADULTS WITH ALLERGIC ASTHMA WHO ARE INADEQUATELY CONTROLLED ON INH... | 2014-10-15 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2011-004126-10 | A PHASE Ib/II STUDY OF GDC-0068 OR GDC-0980 WITH ABIRATERONE ACETATE VERSUS ABIRATERONE ACETATE IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL-BASED CHEMOTHERA... | 2022-08-31 | bad-data |
| Reported results | 2011-004377-84 | A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY AND ACTIVITY OF DCDT2980S IN COMBINATION WITH RITUXIMAB OR DCDS4501A IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED... | 2019-02-07 | due-trials |
| Reported results | 2011-004755-39 | A randomized phase II study of Bevacizumab/mFOLFOX6 vs. Bevacizumab/FOLFIRI with biomarker stratification in patients with previously untreated metastatic colorectal cancer | 2015-05-05 | due-trials |
| Reported results | 2011-005539-22 | A PHASE II, OPEN-LABEL, RANDOMIZED STUDY OF MEHD7945A VERSUS CETUXIMAB IN PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK WHO HAVE PROGRESSED DURING OR FOLLOWING PLA... | 2015-06-22 | due-trials |
| Reported results | 2011-005547-27 | A PHASE II, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF FOLFIRI + MEHD7945A VERSUS FOLFIRI + CETUXIMAB IN SECOND LINE IN PATIENTS WITH KRAS WILD-TYPE METASTATIC ... | 2015-09-22 | due-trials |
| Reported results | 2012-000191-41 | A PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE SAFETY AND EFFICACY OF MPSK3169A IN PATIENTS WITH CORONARY HEART DISEASE OR HIGH RISK OF CORONARY HEART DISEASE | 2013-08-08 | due-trials |
| Completed, but no date, and reported results Terminated | 2012-000578-41 | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB (FCFD4514S) IN PATIENTS WITH GEOGRAPHIC ATROPHY WHO HAVE COMPLETED GENENTECH-SPONSORED LAMPA... | bad-data | |
| Ongoing | 2012-000729-28 | MULTICENTER STUDY IN PATIENTS WITH CROHN?S DISEASE FOR CHARACTERIZATION OF MAGNETIC RESONANCE ENTEROGRAPHY ASSAYS FOR ASSESSMENT OF DISEASE ACTIVITY Estudio multicéntrico en pacientes con enfermeda... | not-yet-due | |
| Exempt, with results | 2012-002042-21 | AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS AND IN COMBINATION WITH ENDOCRINE THERA... | 2021-06-25 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2012-002080-10 | A RANDOMIZED, PHASE II, PLACEBO-CONTROLLED STUDY OF GDC-0068, AN INHIBITOR TO AKT, IN COMBINATION WITH FLUOROPYRIMIDINE PLUS OXALIPLATIN IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC OR GAST... | 2021-01-26 | bad-data |
| Reported results | 2012-002245-37 | A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MCMV5322A/MCMV3068A FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN HIGH-RISK KIDNEY ALLOGRAFT RECIPIENTS | 2014-11-22 | due-trials |
| Reported results | 2012-003242-33 | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY EXTENSION OF PHASE II STUDIES ABE4869g AND ABE4955g IN PATIENTS WITH MILD TO MODERATE ALZHEIMER?S DISEASE ESTUDIO MULTICÉNTRICO, ABIERTO, DE EXTENSIÓN A ... | 2017-02-08 | due-trials |
| Reported results | 2012-003262-41 | A PHASE II, RANDOMIZED STUDY OF PACLITAXEL WITH GDC-0941 VERSUS PACLITAXEL WITH PLACEBO IN PATIENTS WITH LOCALLY RECURRENT OR METASTATIC BREAST CANCER | 2015-12-10 | due-trials |
| Reported results | 2012-005776-34 | A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY AND ACTIVITY OF DNIB0600A COMPARED TO PEGYLATED LIPOSOMAL DOXORUBICIN ADMINISTERED INTRAVENOUSLY TO PATIENTS WITH PLATINUM-R... | 2016-08-17 | due-trials |
| Reported results | 2013-000177-69 | A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF ATEZOLIZUMAB (MPDL3280A) IN PATIENTS WITH PD-L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | 2017-12-18 | due-trials |
| Reported results | 2013-000568-28 | A PHASE II RANDOMIZED, DOUBLE-BLIND STUDY OF NEOADJUVANT LETROZOLE PLUS GDC-0032 VERSUS LETROZOLE PLUS PLACEBO IN POSTMENOPAUSAL WOMEN WITH ER-POSITIVE/HER2-NEGATIVE, EARLY STAGE BREAST CANCER | 2017-03-13 | due-trials |
| Reported results | 2013-001983-52 | A randomized, double-blind, placebo-controlled, phase 2a study in healthy volunteers, to evaluate the efficacy and safety of MHAA4549A in an Influenza challenge model | 2014-06-20 | due-trials |
| Reported results | 2013-003233-15 | A multicenter, randomized, double-blind, placebo-controlled pilot study of quilizumab in patients with refractory chronic spontaneous urticaria (CSU). | 2014-10-22 | due-trials |
| Reported results | 2014-000461-43 | A PHASE 2 RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY IN COMBINATION WITH OSELTAMIVIR VERSUS OSELTAMIVIR FOR TREATMENT OF SEVERE INFLUENZA A INFECTION | 2017-08-07 | due-trials |
| Reported results | 2014-000469-35 | A RANDOMIZED, PHASE II, MULTICENTER, PLACEBO-CONTROLLED STUDY OF IPATASERTIB (GDC-0068), AN INHIBITOR OF AKT, IN COMBINATION WITH PACLITAXEL AS FRONT-LINE TREATMENT FOR PATIENTS WITH METASTATIC TRIPLE... | 2019-08-31 | due-trials |
| Reported results | 2014-003029-16 | A phase II randomized, double-blind study of ipatasertib (GDC-0068), an inhibitor to Akt in combination with paclitaxel as neoadjuvant treatment for patients with early stage triple negative breast ca... | 2017-08-02 | due-trials |
| Exempt, with results | 2014-004852-77 | AN OPEN-LABEL, PHASE I/IIA STUDY OF GDC-0810 IN POSTMENOPAUSAL WOMEN WITH LOCALLY ADVANCED OR METASTATIC ESTROGEN RECEPTOR POSITIVE BREAST CANCER ESTUDIO ABIERTO EN FASE I/IIA CON GDC 0810 EN MUJER... | 2020-03-13 | not-yet-due |
| Reported results | 2015-000106-19 | A PHASE II, OPEN-LABEL, RANDOMIZED STUDY OF GDC-0810 VERSUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER RESISTANT TO AROMATASE INHIBITOR THERAPY | 2020-02-28 | due-trials |
| Completed, report not yet due | 2015-004616-37 | An open-label, multicenter, biomarker study to explore the mechanism of action of ocrelizumab and B-cell biology in patients with relapsing multiple sclerosis or primary progressive multiple sclerosis | 2023-04-11 | not-yet-due |
| Reported results | 2016-000335-40 | A TWO-COHORT RANDOMIZED PHASE II, DOUBLEBLIND, PARALLEL GROUP STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS EVALUATING THE EFFICACY AND SAFETY OF GDC-0853 COMPARED WITH PLACEBO AND ADALIMUMAB IN ... | 2018-07-02 | due-trials |
| Reported results | 2016-000425-40 | A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY, ADMINISTERED AS MONOTHERAPY FOR THE TREATMENT OF ACUTE UNCOMPLICATED SEASONAL INFLUENZA A INFECTION IN... | 2017-11-13 | due-trials |
| Reported results | 2016-000498-19 | A PHASE II OPEN-LABEL EXTENSION STUDY OF PATIENTS PREVIOUSLY ENROLLED IN STUDY GA29350 TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITI... | 2019-07-17 | due-trials |
| Reported results | 2016-001039-11 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | 2019-07-16 | due-trials |
| Reported results | 2016-001549-13 | A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO ASSESS THE EFFICACY AND SAFETY OF MSTT1041A IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA | 2019-07-26 | due-trials |
| Reported results | 2016-004165-58 | A PHASE II, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF MOXR0916 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METAST... | 2018-04-25 | due-trials |
| Reported results | 2016-004624-35 | A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT AND DOSE-RANGING STUDY OF GDC-0853 IN PATIENTS WITH REFRACTORY CHRONIC SPONTANEOUS URTICARIA (CSU) | 2019-10-25 | due-trials |
| Reported results Terminated | 2017-001764-37 | A PHASE II, OPEN-LABEL EXTENSION STUDY OF PATIENTS PREVIOUSLY ENROLLED IN STUDY GA30044 TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LU... | 2019-11-18 | due-trials |
| Reported results | 2017-001800-31 | A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF MTAU9937A IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE | 2021-02-15 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-002350-36 | A PHASE II, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF UTTR1147A COMPARED WITH PLACEBO AND ... | 2021-12-15 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-004997-32 | A PHASE II OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF UTTR1147A IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS OR CROHN'S DISEASE | 2022-07-12 | bad-data |
| Ongoing, reported early | 2018-000280-81 | A PHASE II, RANDOMIZED, BLINDED, PLACEBO-CONTROLLED STUDY OF MTIG7192A, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB IN CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-... | not-yet-due | |
| Other | 2018-001773-24 | A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED MELA... | not-yet-due | |
| Reported results | 2018-003429-27 | A PHASE II, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF MSTT1041A IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | 2020-03-11 | due-trials |
| Reported results | 2019-000783-15 | A RANDOMIZED, OPEN-LABEL, TWO PART STUDY TO EXPLORE THE PERFORMANCE OF ENTRECTINIB PROTOTYPE MINI-TABLET FORMULATIONS AND THE EFFECT OF DRUG SUBSTANCE PARTICLE SIZE ON ENTRECTINIB BIOAVAILABILITY IN H... | 2019-08-09 | due-trials |
| Reported results | 2019-000795-41 | A PHASE IIa, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF MTPS9579A IN PATIENTS WITH ASTHMA REQUIRING INHALED CORTICOSTEROI... | 2022-05-19 | due-trials |
| Reported results | 2019-001897-27 | A PHASE II, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF BFKB8488A COMPARED WITH PLACEBO IN PATIENTS WITH N... | 2023-01-23 | due-trials |
| Ongoing, reported early | 2019-003449-14 | A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE FOLLOWING ADJUVANT PLATINUM-DOUBLET CHEMOTHERAP... | not-yet-due | |
| Reported results | 2020-002713-17 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MSTT1041A OR UTTR1147A IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA ESTUDIO DE FASE ... | 2021-02-12 | due-trials |
| Trial is outside EEC, and reported results | 2020-005916-23 | A Phase IV, Multicenter, Single-Arm, Open-Label Study of Emicizumab Prophylaxis in Patients With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures | bad-data | |
| Ongoing | 2021-002045-15 | A PHASE IIb, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE | not-yet-due | |
| Completed, but no date, and reported results Terminated | 2021-002669-16 | A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT AND DOSE-RANGING STUDY OF MTPS9579A IN PARTICIPANTS WITH REFRACTORY CHRONIC SPONTANEOUS URTICARIA ESTUDIO DE FASE II, MU... | bad-data | |
| Ongoing | 2022-000199-20 | A PHASE III RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR-POS... | not-yet-due |